SNY News & Events

The company states: "ARS Pharmaceuticals announced a CEO succession, in which co-founder and CEO Richard Lowenthal will no longer serve as an employee and officer of the company effective July 6, 2026. The Board has appointed Donn Casale, currently President, as CEO and Director effective July 7, 2026. Mr. Casale brings more than 25 years of biopharmaceutical business and commercial leadership, with a track record of scaling innovative products in large, patient-driven healthcare markets. Prior to ARS Pharma, he served as Chief Commercial Officer at Dynavax Technologies, where he built the U.S. commercial infrastructure and helped scale the hepatitis B vaccine HEPLISAV-B(R) from launch to more than $300 million in annualized revenue and over 50% U.S. market share, positioning the company for Sanofi's $2.2B acquisition."

Catch up on the top artificial intelligence news and commentary by Wall Street analysts on publicly traded companies in the space with this daily recap compiled by The Fly.NEW UNIT:Francessca Vasquez, Vice President of Frontier AI Engineering and Services, AWS, said in a blog post, "I'm excited to announce that we are meeting that demand by creating a dedicated AWS Forward Deployed Engineering organization. Backed by a $1B investment, the AWS FDE model is different in three key ways: it is agentic-first, it compresses timelines from months to days, and it is designed so customers are self-sufficient when a deployment ends. AWS FDE embeds AWS frontier teams-working with purpose-built agents-directly inside customer teams. These experienced engineers, many of whom build our AWS AI services, partner with a customer's business, engineering, and security teams to build and deploy production AI systems with their data, governance, and processes. Unlike traditional consulting that assesses, recommends, and treats each deployment as a standalone project, AWS FDE builds for the long term. Customers leave AWS FDE deployments with both new solutions and new engineering capabilities. Along with agentic systems running in their own AWS environment, they gain lasting AI skills, workflows, and patterns they can use to innovate independently. Deployments are structured around shared goals and business results, not billable hours. When customers succeed, we succeed."CLAUDE SCIENCE:Anthropic has launched Claude Science, a version of its AI tailored for scientific and pharmaceutical research, marking a broader push to become a major platform in biology and life sciences backed by rapidly growing scale and financial resources comparable to leading drug companies, STAT's Matthew Herper and Brittany Trang. Publicly traded companies in the pharmaceutical space include AstraZeneca, Bristol Myers, Eli Lilly, GSK, Johnson & Johnson, Merck, Novartis, Pfizer, Rocheand Sanofi.CLAUDE APPS GETAWAY:Anthropic introduced the Claude apps gateway for Amazon Bedrock and Google Cloud. Previously, running Claude Code on these platforms has meant provisioning a cloud credential per developer, manually pushing settings to every laptop, and standing up separate tooling to see per-developer spend. The gateway is a self-hosted control plane that gives you corporate SSO login, centrally enforced policy, role-based access, and per-user cost attribution for Claude Code. The gateway is run as a single stateless container deployed on Linux and backed by a PostgreSQL database. It holds your upstream credential, authenticates developers against your identity provider, distributes and enforces managed settings, and reports per-user usage to a collector you operate. Onboarding a developer means adding them to your Identity Provider. Offboarding means removing them.Meanwhile, Anthropic said that, starting Monday, Claude models are generally available in MicrosoftFoundry, hosted on Azure. "Claude runs in your Azure environment with the authentication, billing, and governance controls your teams already use," Anthropic said. "You can choose where inference is processed, including a US data zone for teams with data residency requirements. Anthropic operates the inference and is the data processor."

Anthropic has launched Claude Science, a version of its AI tailored for scientific and pharmaceutical research, marking a broader push to become a major platform in biology and life sciences backed by rapidly growing scale and financial resources comparable to leading drug companies, STAT's Matthew Herper and Brittany Trang report. Publicly traded companies in the pharmaceutical space include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

MacroGenics (MGNX) announced that it will receive a $24.5M regulatory milestone payment from Sanofi (SNY) following the U.S. Food and Drug Administration's accelerated approval of TZIELD to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 type 1 diabetes. The approval expands the therapeutic potential of TZIELD as a disease-modifying therapy for type 1 diabetes. Under the terms of MacroGenics' agreement with Sanofi, the recent FDA approval triggered a $24.5M regulatory milestone payable to MacroGenics. The Company remains eligible to receive up to $305M in additional milestone payments and retains the right to receive a single-digit royalty on global net sales above a specified annual threshold.